OncoMatch/Clinical Trials/NCT07066098
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Is NCT07066098 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies IBI343 for pancreatic cancer.
Treatment: IBI343 — This is a study of a Multicenter, Randomized, Double-Blind, Phase III Study of IBI343 Monotherapy Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Participants with Claudin (CLDN) 18.2-Positive, Locally Advanced Unresectable or Metastatic Pancreatic Cancer Who Received at least 2 Prior Lines of Therapy. The primary objective of this study is to determine Overall Survival (OS) of IBI343 plus best supportive care (BSC) compared with placebo plus BSC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: CLDN18 positive
Confirmed as CLDN18.2 positive.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: fluorouracil-based therapy
Have received and progression after at least two systemic therapies (must including a fluorouracil-based and a gemcitabine-based therapy).
Must have received: gemcitabine-based therapy
Have received and progression after at least two systemic therapies (must including a fluorouracil-based and a gemcitabine-based therapy).
Cannot have received: topoisomerase inhibitor-based antibody-drug conjugate
Prior treatment with topoisomerase inhibitor-based ADC.
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify